A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. NEUTON study.
Phase of Trial: Phase IV
Latest Information Update: 04 Apr 2017
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- Acronyms NEUTON
- Sponsors Bayer
- 01 Apr 2017 Status changed from recruiting to completed.
- 01 Aug 2014 New trial record